U.S. market Closed. Opens in 10 hours 1 minute

SMMT | Summit Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 18.80 - 20.56
52 Week Range 1.6400 - 33.89
Beta 0.24
Implied Volatility 87.69%
IV Rank 5.38%
Day's Volume 1,903,857
Average Volume 5,109,896
Shares Outstanding 737,094,965
Market Cap 14,712,415,501
Sector Healthcare
Industry Biotechnology
IPO Date 2015-03-05
Valuation
Profitability
Growth
Health
P/E Ratio -86.78
Forward P/E Ratio N/A
EPS -0.23
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 105
Country USA
Website SMMT
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
SMMT's peers: EPIX, NKTX, CGEM, KZR, KRON, ZVSA, OCEA, ZURA, ELEV, ICVX, PHIO, SONN, ATNF, CDIO
*Chart delayed
Analyzing fundamentals for SMMT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see SMMT Fundamentals page.

Watching at SMMT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on SMMT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙